Physician profile
Diego Ramos-Rivera
NPI 1851349591
$3,662.25
in general payments reported to CMS, 2019-2025
31 companies · $855 in 2025
The $855 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,120 · 2020: $427 · 2021: $288 · 2022: $309 · 2023: $268 · 2024: $395 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $593.00 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $467.26 | 2019-2025 | |
| Novo Nordisk INC | $335.33 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $237.86 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $218.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $193.89 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $165.84 | 2019-2024 | Breztri |
| Silk Road Medical, INC. | $165.22 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $153.15 | 2021 | |
| Coloplast Corp | $144.65 | 2020 | |
| Ucb, INC. | $124.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.01 | 2019-2020 | |
| Astellas Pharma US INC | $109.25 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $86.93 | 2020-2024 | Gardasil 9, Gardasil, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $80.05 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $77.28 | 2022-2025 | |
| Glaxosmithkline, LLC. | $66.41 | 2019-2025 | Shingrix |
| Abbott Laboratories | $57.23 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $40.95 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $29.05 | 2024-2025 | Voquezna |
| Neurocrine Biosciences, INC. | $26.90 | 2024 | Ingrezza |
| Globus Medical, INC. | $22.71 | 2025 | Senza |
| Sumitomo Pharma America, INC. | $22.31 | 2025 | Gemtesa |
| Amarin Pharma, INC. | $20.89 | 2019 | |
| Eisai INC. | $17.66 | 2025 | |
| Boston Scientific Corporation | $17.44 | 2025 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.66 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.33 | 2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $14.75 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.29 | 2019 | |
| Allergan, INC. | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Ramos-Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.